Today’s WSJ includes a review I wrote of an interesting new book about innovation, Little Bets, written by Peter Sims. His thesis is that innovation proceeds through a series of small, experimental steps, requiring an iterative, self-correcting process.
This raises a number of questions directly relevant for biopharma. While some of these issues are discussed elsewhere, one additional question to think about is the challenge of making evolutionary changes in a business – such as drug development — characterized by long cycle times and little robust intermediate insight into how well your approach is fundamentally working.
To read the full, original article click on this link: How Long Timelines Cramp Pharma Innovation - Science Business - research, innovation & policy - Forbes
Author: David Shaywitz
